No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CDMO Avid Bioservices
- 7.700
- +1.000+14.93%
Close Jul 3 13:00 ET
- 7.700
- +0.000+0.00%
Post 15:32 ET
489.57MMarket Cap-3452P/E (TTM)
7.880High6.610Low1.45MVolume6.700Open6.700Pre Close10.79MTurnover2.62%Turnover RatioLossP/E (Static)63.58MShares14.27552wk High8.04P/B425.86MFloat Cap4.07152wk Low--Dividend TTM55.31MShs Float116.375Historical High--Div YieldTTM18.96%Amplitude1.540Historical Low7.452Avg Price1Lot Size
Post-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Why Avid Bioservices Stock Is Moving Higher Wednesday
Avid Bioservices, Inc. (NASDAQ:CDMO) shares are trading higher on Wednesday following the company reporting better-than-expected 2024 fiscal-year fourth quarter sales.The Details: Avid reported fourth
Avid Bioservices Shares Rise on Upbeat FY25 Outlook
By Michael Susin Avid Bioservices shares rose on Wednesday after the group said it expects revenue to sharply increase in fiscal 2025 and to generate positive cashflow and despite posting a widened f
Avid Bioservices Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/03/2024 19.4% RBC Capital $8 → $8 Reiterates Outperform → Outperform 04/30/2024 19.4% RBC Capital $7 →
Craig-Hallum Maintains Avid Bioservices(CDMO.US) With Buy Rating, Announces Target Price $16
Craig-Hallum analyst Matt Hewitt maintains $Avid Bioservices(CDMO.US)$ with a buy rating, and sets the target price at $16.According to TipRanks data, the analyst has a success rate of 39.4% and a tot
RBC Capital Maintains Avid Bioservices(CDMO.US) With Buy Rating, Maintains Target Price $8
RBC Capital analyst Sean Dodge maintains $Avid Bioservices(CDMO.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 39.2% and a t
RBC Capital Sticks to Its Buy Rating for Avid Bioservices (CDMO)
Comments
Investors' belief in Societal CDMO's lackluster revenue performance not improving may be causing its low P/S ratio. The company's inferior revenue outlook compared to the industry average contributes to this. A significant change in fortune is needed to justify a higher P/S.
Societal CDMO, Inc.'s (NASDAQ:SCTL) Shares Bounce 29% But Its Business Still Trails The Industry 1
The company's high debt and lack of profitability strain its balance sheet. Negative free cash flow adds risk, but its US$417.4m market cap could potentially allow capital raising to strengthen the balance sheet.
Investors' belief in Avid Bioservices' stagnant revenue performance and future growth lagging behind the industry has led to its low P/S. The underwhelming revenue outlook and shareholders' pessimism impact the P/S negatively.
Despite good revenue growth, the market expected more, as seen in the share price drop. This could hint at delayed revenue growth. The recent sell-off might be an investment chance considering the signs of a continued growth trend.
$FedEx(FDX.US$ $La-Z-Boy(LZB.US$ $Dynagas LNG Partners LP(DLNG.US$ $Winnebago Industries(WGO.US$ $KB Home(KBH.US$ $Algoma Steel(ASTL.US$ $Steelcase(SCS.US$ $Avid Bioservices(CDMO.US$ $Accenture(ACN.US$ $Darden Restaurants(DRI.US$ $FactSet Research Systems(FDS.US$ $Globex Mining Enterprises Inc(GMX.CA$ $GMS Inc(GMS.US$ $Commercial Metals(CMC.US$ $Methode Electronics(MEI.US$ $CAPSTONE COMPANIES INC(CAPC.US$ $CarMax(KMX.US$ $Apogee Enterprises(APOG.US$
...
...
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg